Last reviewed · How we verify
INCAGN01876
At a glance
| Generic name | INCAGN01876 |
|---|---|
| Also known as | Anti-GITR agonist, GITR |
| Sponsor | Providence Health & Services |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma (PHASE2)
- Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies (PHASE1, PHASE2)
- Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCC (PHASE1)
- Biomarker-based Study in R/M SCCHN (PHASE2)
- INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (PHASE2)
- INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies (PHASE1, PHASE2)
- A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |